Subject: counsyl Q4 Update
From: "John DeLoche" <[email-masked]>
To: "Hunter Biden" <[email-masked]>, "Devon Archer" <[email-masked]>, "Neil Callahan" <[email-masked]>, "William Lee" <[email-masked]>, "Eric Schwerin" <[email-masked]>, "Rob Walker" <[email-masked]>
Date: Fri, 7 Feb 2014 14:50:20 -0800

Gents,

Great seeing you all in NY and DC this week. We are on our way to building
the world's best growth equity firm.

I just got off the Counsyl Q4 update call and they continue to crush it.
Update is below:

$48.3mm revenues in 2013

Forecasting $88mm to $100mm for 2014

Grew salesforce from 30 to 60 people last year. Growing salesforce to 100
people in 2014

International expansion. hiring someone this month. Will determine what
markets to enter in Q1/Q2.

Plan to complete CFO hire by end of Q1.

Spring marketing relaunch and new website in May. Likely large growth
equity round in 2h 2014, IPO in 2015

33k requisitions in  Q4 which was 7% QoQ growth

Introduced breast cancer (BRCA) test last year. 5k BRCA tests by Q4 2014

Expanding into hereditary cancer testing as well as newborn screening.
Timing of hereditary cancer test introduction is Q1 2015.

There is an in person board meeting next week and I will send a further
update then.

Best,

John

John DeLoche
*Managing Director*
Rosemont Seneca Technology Partners
333 Bush Street, 21st Floor
San Francisco, CA 94104
office: 415 767 1288
mobile: 415 793 7070

This email communication is privileged and confidential and is intended
only for the individuals or entities named above. Any unauthorized
dissemination of any of the contents of this email is strictly prohibited.
If you are not the intended recipient, please do not read, copy, use or
disclose to others the contents of this communication. Please notify the
sender that you have received this e-mail in error and then delete the
e-mail